4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
4D Molecular Therapeutics, Inc. (FDMT) reported a Q3 loss of $0.79 per share, missing the Zacks Consensus Estimate of a $0.67 loss. This is a larger loss compared to $0.24 per share a year ago.
November 13, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
4D Molecular Therapeutics reported a larger-than-expected Q3 loss of $0.79 per share, missing the consensus estimate of $0.67 and widening from last year's $0.24 loss.
The reported loss per share of $0.79 is worse than the expected $0.67, indicating a negative earnings surprise. This, combined with a significant increase in loss from the previous year, is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100